Mirum Pharmaceuticals Reports Positive Phase 2b Results for Brelovitug in Chronic Hepatitis Delta Virus
MIRM has more than doubled off its 52-week low of $39.51.
Summary
Mirum Pharmaceuticals reported positive Phase 2b results for its investigational drug brelovitug in chronic hepatitis delta virus, meeting the primary endpoint with strong efficacy and a favorable safety profile.
Key Events · Product Development and Regulatory · MIRM
-
Brelovitug Meets Primary Endpoint in AZURE-1 Study
The Phase 2b portion of the AZURE-1 study for brelovitug, an investigational monoclonal antibody for chronic hepatitis delta virus (HDV), met its primary endpoint.
-
Demonstrates Robust Antiviral Activity
100% of patients in the 300 mg QW arm and 75% in the 900 mg Q4W arm achieved virologic response, compared to 0% in the delayed treatment arm. The primary composite endpoint was achieved in 45% and 35% of patients, respectively.
-
Well-Tolerated Safety Profile
Treatment with brelovitug was well tolerated across dose groups, with a favorable safety profile.
-
Clear Path to Market
Topline data from Phase 3 studies are expected in H2 2026, with potential BLA submission and commercial launch in the U.S. in 2027.
Analysis · MIRM · Life Sciences
Mirum Pharmaceuticals announced highly positive Phase 2b results for brelovitug in treating chronic hepatitis delta virus (HDV), a significant de-risking event for the program. The drug demonstrated robust antiviral activity, with 100% and 75% virologic response rates in the two dose arms, respectively, compared to 0% in the control group. The primary composite endpoint of virologic response and ALT normalization was also met with strong statistical significance. The favorable safety profile further supports its potential as a single-agent therapy. These results pave a clear path towards anticipated Phase 3 data in H2 2026 and a potential BLA submission and commercial launch in 2027, significantly enhancing the company's pipeline value and future revenue prospects.
At the time of this filing, MIRM was trading at $92.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $39.51 to $109.28. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.